98%
921
2 minutes
20
Context: Individually, bone resorption or formation markers do not reflect bone balance.
Objective: (1) Combine reference bone resorption [collagen type I C-telopeptide (CTX)] and formation [procollagen type I propeptide (PINP)] markers to estimate balance by creating a bone balance index (BBI); (2) examine associations of BBI, CTX, or PINP with bone mineral density (BMD) change.
Design: Mixed effects linear regression quantified associations of BBI, CTX, or PINP with BMD change rate.
Setting: Community-based cohort (Study of Women's Health Across the Nation).
Participants: 535 women transitioning through menopause.
Main Outcome Measures: Annualized percent change in lumbar spine (LS) and femoral neck (FN) BMD.
Results: In mixed effects linear regression, adjusted for age, body mass index, race/ethnicity, menopause transition stage, and study site, more negative BBI (less favorable balance) related to more BMD loss. Each SD decrement in BBI was associated with a 0.26% greater decline in LS BMD annually and 0.42% greater decline in FN BMD annually (each P < .0001). In separate models, accounting for the previous covariates, greater CTX or PINP predicted more bone loss. Per SD increment in log2CTX, annual BMD decline was 0.37% greater (P < .0001) and 0.47% greater (P < .0001) at the LS and FN, respectively. Per SD increment in log2PINP, annual BMD loss was 0.22% (P < .0001, LS) and 0.19% (P = .01, FN) greater.
Conclusion: When combined as a BBI, CTX and PINP estimate bone balance; more negative BBI predicts faster BMD loss. Separately, CTX or PINP reflect overall amount of bone turnover; greater CTX or PINP are related to more bone loss.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261099 | PMC |
http://dx.doi.org/10.1210/clinem/dgae842 | DOI Listing |
Arch Gerontol Geriatr
August 2025
Department of Orthopedics Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China; Orthopedics Research Institute of Zhejiang University, Hangzhou 310009, China; Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Provinc
Postmenopausal osteoporosis (PMOP) features reduced bone mass and deteriorated bone microstructure, increasing fracture risk. Estrogen deficiency-induced osteoclast overactivation is a primary driver. OCP-001, a novel highly selective HDAC1 inhibitor, was investigated.
View Article and Find Full Text PDFBMC Musculoskelet Disord
September 2025
Department of Orthopedics, Jiande First People's Hospital, No. 599, Yanzhou Avenue, Xin'anjiang Street, Jiande City, Hangzhou, Zhejiang Province, 311600, China.
Objective: Pentraxin 3 (PTX3) is an acute-phase protein of the pentraxin family, primarily secreted by immune cells and endothelial cells. This study analyzed its correlation with the severity of postmenopausal osteoporosis (PMOP) and its prognostic value.
Methods: Postmenopausal women (n = 405) were retrospectively selected and arranged into normal bone mineral density (BMD), osteopenia, and PMOP groups.
Int J Obes (Lond)
August 2025
Institute of Biomedicine, University of Turku, Turku, Finland.
Background: Obesity suppresses bone turnover markers (BTMs) in circulation, and weight loss after metabolic and bariatric surgery (MBS) increases BTM levels. However, the relationship between regional fat distribution and BTMs has not been thoroughly investigated. This study aimed to determine which specific fat compartments - namely abdominal and femoral subcutaneous fat (SF), intraperitoneal fat, extraperitoneal fat, and total visceral fat (VF) - have the greatest impact on circulating BTM levels following weight loss induced by MBS.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
August 2025
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Context: Oral glucose tolerance test (OGTT) induces greater acute suppression of bone resorption than isoglycaemic intravenous glucose infusions (IIGI).
Objective: To study the separate and combined effects of the gut-derived hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2) on postprandial bone turnover.
Design: A randomized, crossover study with 6 experimental days.
Curr Med Chem
August 2025
Department of Medical Physiology, School of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Introduction: One of the most effective osteoanabolic drugs for treating osteoporosis is romosozumab, which was developed as a consequence of growing knowledge of the Wnt signaling system. This review explored how romosozumab affects the bone mineral density (BMD) in osteoporotic patients.
Methods: Up until January 2024, PubMed, Web of Science, and Scopus were reviewed for any randomized controlled trials (RCTs) evaluating the impact of osteoporotic treatment with romosozumab on BMD changes and bone metabolism markers in primary osteoporosis patients.